Myositis ossificans circumscripta after surgery and radiotherapy and during sunitinib treatment: a case report.

Autor: Cren PY; Département d'oncologie Médicale, Centre Oscar Lambret, 3 Rue Frédéric Combemale, 59000, Lille, France. p-cren@o-lambret.fr.; Université de Lille, Lille, France. p-cren@o-lambret.fr., Penel N; Département d'oncologie Médicale, Centre Oscar Lambret, 3 Rue Frédéric Combemale, 59000, Lille, France.; Université de Lille, Lille, France., Cordoba A; Département de Radiothérapie, Centre Oscar Lambret, Lille, France., Decanter G; Département de Chirurgie, Centre Oscar Lambret, Lille, France., Gaboriau L; Centre Régional de Pharmacovigilance, Service de Pharmacologie Médicale, CHU Lille, Lille, France., Ben Haj Amor M; Département d'imagerie Médicale, Centre Oscar Lambret, Lille, France.
Jazyk: angličtina
Zdroj: Journal of medical case reports [J Med Case Rep] 2022 Dec 07; Vol. 16 (1), pp. 454. Date of Electronic Publication: 2022 Dec 07.
DOI: 10.1186/s13256-022-03664-5
Abstrakt: Background: Myositis ossificans circumscripta is a self-limiting, benign, ossifying lesion that can affect any type of soft tissue. It is most commonly found in muscles as a solitary lesion. A history of recent trauma has been reported in approximately 50% of cases. Clinically, MOC presents as a painful swelling, which rapidly increases in size. The pain and inflammatory symptoms spontaneously disappear after approximately 2-6 weeks, and the mass stabilizes or decreases. Radiologically, myositis ossificans circumscripta can be divided into two phases. The first is the acute phase, which is followed by the mature phase 2-6 weeks later. During the acute phase, the radiological aspect does not show any specific abnormality. In the mature phase, plain radiographs and computed tomography show blurred calcifications around a hypodense center. We describe here the first case of myositis ossificans circumscripta, with appropriate follow-up, occurring during sunitinib exposure.
Case Presentation: We report a case of myositis ossificans circumscripta in a 34-year-old man (ethnicity unknown) receiving sunitinib for metastatic alveolar soft part sarcoma of the left thigh after surgery and radiotherapy. Four months after the first dose of sunitinib, the patient experienced painful swelling in the surgical scar area. Magnetic resonance imaging showed diffuse and marked edema of the anterior compartment of the thigh, without nodular lesions circumscribing a central core, and without bone signal abnormality. The increased visibility of the intermuscular fascia and convergence of normal muscle fibers (black hole effect), without the displacement seen in tumors, were suggestive of myositis. Therefore, antiangiogenic treatment was discontinued, and the symptoms rapidly resolved within a few days. Three weeks after the discontinuation of sunitinib, the inflammatory findings completely disappeared. Two months after the diagnosis of myositis ossificans circumscripta, plain radiographs and computed tomography showed an extensive calcified mass measuring > 12 cm. The continuation of favorable clinical outcomes was confirmed.
Conclusions: To the best of our knowledge, this is the first case of myositis ossificans circumscripta with appropriate follow-up occurring during sunitinib exposure. Owing to multimodal treatment of sarcoma, we cannot rule out the radiotherapy and surgery causality.
(© 2022. The Author(s).)
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje